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Tetraspanin proteins form signaling complexes between them
and with other membrane proteins and modulate cell adhesion
and migration properties. The surface expression of several
tetraspanin antigens (CD9, CD37, CD53, CD63, and CD81), and
their interacting proteins (CD19, CD21, and HLA-DR) were
analyzed during normal B-cell maturation and compared to a
group of 67 B-cell neoplasias. Three patterns of tetraspanin
expression were identified in normal B cells. The first
corresponded to bone marrow CD10þ B-cell precursors (BCP)
which showed high expression of CD81 and CD9, low reactivity
for CD53 and negativity for CD37. CD10 B-lymphocytes
showed downregulation of CD9/CD81 and upregulation of
CD53/CD37. Plasma cells showed re-expressed CD9 and down-
regulated CD37. Hierarchical clustering analysis of flow cyto-
metry immunophenotypic data showed a good correlation
between the tumor differentiation stage and the pattern of
tetraspanin expression, with all analyzed individual samples
classified into three major groups, independently of their
normal or neoplastic origin. Despite this, neoplastic B-cells
frequently showed aberrantly high/low expression of the
different markers analyzed. Interestingly, in B-cell chronic
lymphocytic leukemia, abnormal expression of CD53 and CD9
were associated with different patterns of disease infiltration,
which would support the role of these molecules on modulating
adhesion and migration of neoplastic B cells.
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Introduction
Tetraspanin proteins are a group of structurally related
membrane proteins involved in cell adhesion1–7 motility8–16
and apoptosis;17 the exact mechanisms through which they
modulate these processes remains unknown. They have four
common transmembrane domains with four, six or eight
cysteine residues and a CCG motif in the largest extracellular
loop.18,19 In all, 25 members have been identified so far.
Although the expression of some of these molecules is limited
almost exclusively to lymphoid or myeloid cells (eg CD37),
most tetraspanin are widely expressed in many non,hemato-
poietic cell types (eg CD9, CD63 and CD81).20,21 Mammalian
cells simultaneously express several tetraspanin antigens, which
might form specific complexes on the plasma mem-
brane.15,18,22–24
On the cell surface, tetraspanin antigens are present either as
free molecules or through interaction with other proteins.25,26
These interacting proteins include other tetraspanins, integri-
nsFparticularly those with the b1 subunit 22,27–30FHLA class II
moleculesFeg HLA DR31–33-, CD19,34,35 the T-cell recep-
tor36,37 and several other members of the immunoglobulin
superfamily.38 As an example, CD81 binds to a CD19/CD21
complex on B-cells,39 as well as to CD9 and CD82.35 The
diversity in the composition of tetraspanins, and those proteins
interacting with the tetraspanin-containing membrane com-
plexes allows for a larger plasticity of their signaling proper-
ties.15,23,24 Overall, it is likely that the pattern of expression of
tetraspanin proteins is a major determining factor in the specific
adhesion and homing properties of a cell,40 and that changes in
this profile will be followed by a redistribution of the cell within
the organism in terms of its developmental stage or functional
state. As a result of the complex pattern of tetraspanin gene
expression, it is very likely that the adhesion and migration
properties of tumor cells are also influenced by the alteration in
the composition of cell-specific tetraspanin protein complexes.
Abnormal levels of tetraspanin antigens have been identified
in many different types of carcinomas.41,42 In general, low
expression of some individual molecules has been related to a
poor prognosis. Accordingly, low levels of CD63 in melano-
mas43 as well as in colon carcinomas42 indicated a higher
metastatic potential. Additional correlations between abnor-
mally low levels of tetraspanin molecules and poor prognosis
have been reported for CD9 in the lung,9 oral,44 cervical45 and
breast carcinomas8 and for CD82 in the prostate,12,46,47 breast48
and lung cancer.49 Interestingly, re-expression of CD950 and
CD8212 in the tumor cells increases their adhesion and
subsequently reduces their motility. Regarding CD53, its
reduced expression in normal cells is associated with a
syndrome very similar to leukocyte adhesion defects, character-
ized by recurrent infections.51
In the present study, we have quantitatively analyzed the
distribution and the pattern of expression of several tetraspanin
antigens in normal and neoplastic human B cells. Our results
show a high frequency of aberrant expression of tetraspanin
molecules in tumor B cells. Despite this, the overall pattern of
expression of these proteins during normal B-cell maturation
correlated with the stage of maturation arrest in B-cell
neoplasias, which could be of help for diagnostic purposes.
Materials and methods
Controls and patients
Analysis of the expression of tetraspanin molecules and other
functionally related surface proteins along the normal B-cell
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differentiation was performed on a total of 17 normal samples
obtained from subjects without any known disease and with
normal blood cell counts: six bone marrow (BM) and nine
peripheral blood (PB) samples obtained from an identical
number of healthy adult volunteers and two reactive lymph
node samples. In turn, normal residual plasma cells (PC) were
analyzed in three BM samples from an identical number of
patients with monoclonal gammopathy of undetermined sig-
nificance (MGUS).
In addition, a total of 25 BM, 41 PB and one lymph
node sample from a total of 67 newly diagnosed untreated
patients with clonal B-cell malignancies, were studied.
Diagnosis of the different B-cell malignancies was based on
clinical, morphologic, immunophenotypic and molecular cri-
teria, according to the WHO classification.52 Patients
were distributed as follows: CD34þ precursor B acute
lymphoblastic leukemia (B-ALL), eight patients FBII: seven,
one being t(bcr/abl)þ , BIII: 1_;53 CD34 precursor B-ALL,
four patientsFall BIII (one with t(8;14)þ and another
with t(12;21)þ );53 B-cell chronic lymphocytic leukemia (B-
CLL), 28 patientsF25 typical (typ) and three atypical (atyp)
B-CLL; prolymphocytic leukemia (PLL), one patient; hairy
cell leukemia (HCL), two; mantle cell lymphoma (MCL),
threeFall being t(11;14)þ ; splenic marginal zone lymphoma
(SMZL), one; MALT lymphoma, five cases; follicular lymphoma
(FL), two patientsFboth being t(14;18)þ ; bcl6þ diffuse large
B-cell lymphoma (DLBCL), one patient; Burkitt‘s lymphoma,
two patientsFone being t(8;14)þ ; multiple myeloma (MM), five
patients; and MGUS, five cases. Samples from both the patients
and the controls were obtained after informed consent,
according to the Ethics Committee of the University Hospital
of Salamanca (Salamanca, Spain).
Flow cytometry immunophenotypic studies
All normal and neoplastic PB and BM samples were collected in
tubes containing K3-ethylenediaminotetraacetic acid (EDTA) as
anticoagulant. BM samples were immediately diluted 1/1
(vol/vol) in phosphate-buffered saline (PBS). Lymph node
samples were obtained by fine-needle aspiration, according to
well-established procedures. Immunophenotypic studies
were performed on erythrocyte-lysed samples using well-
established direct immunofluorescence stain, lyse and then
wash procedures.54 Nucleated cells (1–2 106 cells in
100ml/test) were stained using the following three- and
four-color combinations of monoclonal antibodies (MoAb)
directly conjugated with fluorescein isothiocyanate (FITC),
phycoerythrin (PE), peridin chlorophyll protein (PerCP) and
for four color combinations allophycocyanine (APC): CD63/
CD53/CD19 or CD38; CD9/CD37/CD19 or CD38 and CD21/
CD81/HLA-DR/CD19 or CD38. The source of the MoAb
was as follows: CD19 (clone SJ25C1), CD38 (clone HB7) and
anti-HLA-DR (clone L243) were purchased from Becton Dick-
inson Biosciences (–BDB- San Jose´, CA, USA), CD53 (clone
HI29) and CD81 (clone JS81) were from PharMingen
(San Diego, CA, USA), CD9 (clone CLB-thromb/8,4E1) and
CD63 (clone CLBGran/12) from Immunotech (Marseille,
France), CD21 (clone 1F8) from DakoCytomation (Glostrup,
Denmark) and CD37 (clone HH1) from DIATEC AS (Oslo,
Norway). Stained cells were analyzed in a FACSCalibur flow
cytometer using the CellQuest software program (BDB). For
those samples that had a low proportion of neoplastic cells
(o10% of the whole sample cellularity), as well as in all normal
and MGUS samples, a two-step acquisition procedure was
performed. In the first step, information was stored on a
minimum of 3 104 nucleated cells corresponding to the whole
sample cellularity. In the second step, acquisition through an
electronic ‘live gate’ was carried out; in normal BM and PB
samples, as well as in samples from immature and mature B-cell
malignancies, the electronic ‘live gate’ was drawn on the
CD19þ region in which B-cells are located, while in BM
samples from normal individuals, MGUS and MM patients a
‘live gate’ drawn on the CD38þ þ þ region was applied in order
to specifically select PC. In this second step, information on a
minimum of 104 CD19þ B-cells or CD38þ þ þ , PC was stored.
For data analysis, the Paint-A-Gate PRO software (BDB) was
used. Expression of tetraspanin molecules was assessed in the
following subpopulations of CD19þ B-cells and/or CD38þ þ þ
PC: BM CD34þ /CD19þ B-cell precursors (BCP), BM CD34/
CD19þ BCP, PB CD19þ mature B lymphocytes, lymph node
CD19þ B cells and BM CD38þ þ þ PC. For each antigen
analyzed, the intensity of expression was evaluated by the mean
fluorescence intensity (MFI), observed for the specific cell
population under analysis and expressed either as absolute
MFI values (arbitrary relative linear units scaled from 0 to 104) or
as a percentage of the maximum MFI observed for that antigen
in normal B cells.
Statistical methods and hierarchical clustering analysis
Mean values and their standard deviation, as well as median,
range, 25 and 75th percentiles and 95% confidence intervals
were calculated for each variable. Statistical analyses were
performed with the SPSS 11.0 software program (SPSS Inc.,
Chicago, IL, USA). For the evaluation of the statistical
significance of the differences observed between groups, the
Mann–Whitney U-test was used. P values p0.05 were
considered to be associated with statistical significance. In
B-cell neoplasias, antigen overexpression and underexpression
were defined as an MFI higher or lower than the 95%
confidence interval observed for its expression in the corre-
sponding normal B-cell counterpart, respectively. Sensitivity
and specificity were defined as TP/TPþ FN and TN/TNþ FP,
respectively, where TP are true positives, TN true negatives, FN
false negatives and FP correspond to false positives.
Hierarchical clustering analysis was performed using those 72
samples in which all markers of the panel had been tested.
Clustering was run using standard correlation coefficients; for
the cluster method, a similarity metric and average linkage was
used.55 The MFI value obtained for each marker tested was
introduced into a dedicated database system (Microsoft Excel,
Microsoft, Seattle, WA, USA). A ratio between the MFI obtained
for each marker and the mean MFI value obtained for that
marker in all normal samples tested was then calculated.
Clustering was performed after median centering and normal-
izing the fluorescence ratios. A logarithmic (base 2) transforma-
tion was applied to the values of this ratio for individual data
sets. The resulting normalized log2 ratios were used for further
statistical analyses with the J-Express Pro V2.1 software
(MolMine AS, Bergen, Norway).
In order to explore the predictive value of the normal patterns
of expression of tetraspanins and other related molecules, to
properly classify neoplastic B cells according to their stage of
maturation arrest, a class predictor was built using a weighted
voting algorithm evaluated with a leave-one-out cross valida-
tion. For this purpose, a training set of normal B-cell populations
(n¼ 20) grouped into three classes was used: (1) normal BM
BCP; (2) normal mature BM, PB and lymph node B-lympho-
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cytes; and (3) normal BM PC. The accuracy of the predictor was
then tested in a set of 51 neoplastic populations of B cells using
the nearest shrunken centroids method (PAM software; details
may be found at http://www-stat.stanford.edu/~tibs/PAM).56
Results
Expression of tetraspanin antigens and other related
molecules during normal B-cell maturation
In normal BM, three subpopulations of CD19þ B cells were
identified by their differential expression of the CD10 and CD34
antigens. These subsets corresponded to three stages of
increasingly mature B-cells: (I) CD34þ /CD10þ þ , (II) CD34/
CD10þ , and III) CD34/CD10 (Figure 1). In addition, normal
PC were also identified in control BM samples by their
extremely high CD38 expression. Mature B lymphocytes from
both PB and reactive lymph node samples were also studied.
The relative expression of all tetraspanin antigens changed
during normal B-cell development, except CD63Fwhich was
always detected at very low levels on the surface of all B-lineage
cells (Figures 1 and 2). Accordingly, the early CD34þ /CD10þ þ
and late CD34/CD10þ BCP displayed relatively high levels of
CD9 and CD81, but barely detectable amounts of CD37 and
CD53; as these cells differentiated into CD10 B cells, a
significant reduction of CD9 and CD81 expression towards
undetectable amounts was observed, in association with a
dramatic increase in the levels of surface CD37 and CD53.
Interestingly, CD10/CD34 B-lymphocytes in the BM and B
lymphocytes from both normal PB and reactive lymph nodes
showed a similar pattern of tetraspanin expression: high
reactivity for CD53 and CD37 and dim/negative expression of
CD81 and CD9. In turn, PC that have recirculated from
lymphoid tissues back to the BM, lost expression of CD37 and
regained reactivity for CD9, dissociating their expression from
CD53 and CD81, respectively.
Expression of tetraspanin antigens and other related
molecules in neoplastic B cells
In general, a parallel expression of individual tetraspanin
molecules was found in normal and neoplastic B cells. Despite
this, significant differences existed between the two groups
(Figure 2).
Concerning BCP-ALL (left columns from all panels in Figure 2)
variable levels of most tetraspanin antigens were detected in
both the CD34þ and CD34 patient groups. However, as
compared to normal CD34/CD10þ BCP, CD34 BCP-ALL
cases showed overexpression of both CD37 (P¼ 0.05) and
CD53 (P¼ 0.05) while CD34þ BCP-ALL displayed a signifi-
cantly reduced CD81 (P¼ 0.003) expression and higher
reactivity for CD63 (P¼ 0.005) in comparison with normal
CD34þ BCP. No additional significant differences were
observed in either group, regarding the expression of other
tetraspanin molecules. Table 1 shows the exact percentage of
BCP-ALL cases showing abnormally high and low amounts of
each of the proteins analyzed.
Among mature/peripheral chronic B-cell leukemias and non-
Hodgkin’s lymphomas (middle-left columns from all panels in
Figure 2), a pattern of expression of tetraspanin molecules
similar to that of normal mature PB and lymph node
B-lymphocytes, was observed. Despite this, abnormal expres-
sion of specific antigens was found in several individual
diagnostic subgroups (summarized in Table 1). Accordingly, in
B-CLL/PLL cases, identical patterns of expression of tetraspanin
molecules were observed as those found for normal mature
circulating B-lymphocytes, with low CD9 and CD81 expression
and strong reactivity for CD37 and CD53. In spite of this, B-CLL/
PLL patients showed aberrantly low levels of CD81 (P¼ 0.004)
and CD37 (Pp0.001) and abnormally high amounts of CD53
(P¼ 0.005) as compared to normal PB B cells. Interestingly,
among B-CLL cases, aberrantly increased expression of CD53
and decreased reactivity for CD9 correlated with the pattern of
in vivo tissue distribution of neoplastic B cells. Accordingly,
increased reactivity for CD53 was associated with a higher
frequency of lymph node involvement (P¼ 0.02) and greater PB
lymphocytes counts (P¼ 0.02), while cases with decreased
expression of CD9 showed a more pronounced BM infiltration
(P¼ 0.03) and lower PB platelet counts (P¼ 0.02).
In a similar way, although B-NHL generally displayed a
similar profile of tetraspanin molecule expression as normal
circulating PB/lymph node B cells, a significantly higher
expression of CD53 was observed in MALT/SZML patients
(P¼ 0.05). Although only two HCL were studied, both displayed
an almost identical tetraspanin immunophenotype with aber-
rantly high expression of CD53 and CD63, with respect to both
normal mature B lymphocytes and PC (Figure 2).
Clonal PC from patients with MGUS and MM (right columns
in all panels in Figure 2), showed a rather similar pattern of
tetraspanin antigen expression. Once compared to normal B
cells, this pattern was more closely related to that of normal BM
PC. Nevertheless, clonal PC from MM showed significantly
reduced CD9 expression (P¼ 0.01), as compared to their normal
counterparts. Another striking characteristic of tetraspanin
antigen expression in clonal PC relates to the higher amounts
of CD63 detected in MGUS as compared to normal (P¼ 0.09)
and MM (P¼ 0.03) PC, which were at least twenty-fold over
those detected in any normal B cells.
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Figure 1 Pattern of expression of tetraspanins during normal B-cell
maturation. For each molecule, results are expressed in percent values
relative to the maximum value (100%) detected. The absolute values
observed for each antigen are presented in Figure 2. Arrows indicate
the location of changes in the pattern of tetraspanin antigen
expression. The levels of expression of surface CD63 (data not shown)
were always low and similar in all maturation stages analyzed, except
in plasma cells (see Figure 2). PB: peripheral blood. PC: plasma cells.
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Abnormally high expression of the CD21 tetraspanin-associated
molecule was found in both CD34 (P¼ 0.02) and CD34þ
(P¼ 0.007) BCP-ALL and MM (P¼ 0.01). In turn, significantly
reduced levels of CD19 were detected in MALT/SMZL (P¼ 0.01),
MCL (P¼ 0.02), MGUS (P¼ 0.03) and MM (P¼ 0.03), as well as
in a significant proportion (41%) of all B-CLL patients (Tables 1
and 2). In contrast, the pattern of expression of HLADR was
similar in neoplastic B cells and their normal counterparts.
Classification of B-cell neoplasias according to the
expression of tetraspanin and tetraspanin-associated
antigens
Multivariate analysis of flow cytometry data was initially
performed using tools that are usually employed for the analysis
of microarray gene expression, although in this study the values
reflect protein rather than RNA levels. Results of this analysis are
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Figure 2 Expression of the CD9, CD37, CD53, CD63 and CD81 tetraspanin molecules in neoplastic B cells (gray boxes) as compared to their
normal counterparts (white boxes). Results are expressed as mean fluorescence intensity (MFI) in arbitrary units scaled from 0 to 104. The
phenotype of subpopulations of CD19þ BCP, mature CD19þ lymphocytes and CD38þ þ þ plasma cells for both normal and neoplastic B-cells,
are shown in the right, middle-left and left columns of each panel, respectively; the four middle-right panel corresponds to HCL cases. Boxes
extend from the 25 to the 75th percentiles; the line in the middle and the vertical lines represent median values and 95% confidence intervals,
respectively. nPp0.05 with respect to normal bone marrow (BM) cells; nnPp0.05 with respect to normal peripheral blood (PB); zPp0.05 with
respect to reactive lymph node (RLN); #Pp0.05 with respect to clonal PC from MGUS. BCP-ALL: B-cell precursor acute lymphoblastic leukemia;
B-CLL/PLL: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia; FL: follicular lymphoma; DLBCL/BURKITT‘S LYMPHOMA: diffuse
large B-cell lymphoma/ Burkitt’s lymphoma; MALT-L/SMZL: mucos-associated lymphoid tissue lymphoma/splenic marginal zone lymphoma;
MCL: mantle cell lymphoma; MGUS: monoclonal gammopathy of undetermined significance; PC: plasma cells; MM: multiple myeloma; NA: not
analyzed.
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shown in Figure 3. As it illustrates, similar tumors were clustered
together, and at the same time were grouped with the
corresponding normal B-cell population, except for two MM
cases classified together with immature B cells. Overall, three
major groups of B-cell neoplasias were clearly defined: (1) BCP-
ALL; (2) mature B-cell neoplasias (B-cell chronic lymphoproli-
ferative disorders plus B-cell NHL); and (3) PC dyscrasias. Their
normal counterparts included: (1) CD10þ BM BCP; (2) mature
BM, PB or reactive lymph node B lymphocytes; and (3) BM PC.
This is a significant finding taking into consideration the low
number of markers included in the analysis.
Table 1 Frequency of abnormally increased/decreased expression
of tetraspanin and tetraspanin-related molecules in B-cell leukemias/
lymphomas
BCP ALL B-CLL/PLL Other B-CLPD MGUS/MM
n¼ 12 n¼ 29 n¼16 n¼10
CD53
Decreased 25 7 0 0
Increased 25 64 56 10
CD63
Decreased 0 0 0 0
Increased 75 79 6 20
CD81
Decreased 75 90 0 0
Increased 17 0 36 0
CD37
Decreased 25 69 0 0
Increased 25 7 6 0
CD9
Decreased 50 29 0 0
Increased 25 11 19 0
CD19
Decreased 17 41 0 100
Increased 67 35 19 0
CD21
Decreased 0 0 0 0
Increased 100 10 0 20
HLADR
Decreased 36 0 0 0
Increased 27 18 0 10
Results expressed as percentage of cases.
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Figure 3 Hierarchical cluster analysis of surface expression of five
tetraspanin antigens (CD63, CD53, CD9, CD81, CD37) and three
tetraspanin-associated proteins (CD19, CD21, HLADR) in normal
(n¼ 20) and neoplastic B cells (n¼52). Mean fluorescence intensity
(MFI) values obtained for each antigen by flow cytometry immuno-
phenotyping were imported and analyzed. Rows represent the
individual subpopulation of B cells analyzed from both normal and
neoplastic samples and columns represent the normalized log2 ratios
of the MFI obtained for each marker divided by the mean MFI value
obtained for that marker in all normal samples tested, for each protein
analyzed. The relative level of expression of each molecule is
represented in a color code: red represents expression greater than
the mean, green represents expression lower than the mean and the
color intensity represents the magnitude of the deviation from the
mean; as indicated, the scale extends from ratios of 6.678 to þ6.678
(log 2 units).
Table 2 Clinical and biological characteristics of B-CLL patients associated with the pattern of expression of tetraspanin molecules
CD53 CD9
Normal/decreased Increased Decreased Normal/increased
Adenomegalies 14% 69%* 29% 62%
Diffuse pattern of BM infiltration 50% 11% 100%* 10%
% Lymphocytes in BM 67730 51727 9371* 43721
PB platelet counts (109/l) 1947120 206763 137764* 235772
PB lymphocyte counts ( 109/l) 975 25717* 19714 20717
Categorical variables shown as percentage of cases within each group. Continuous variables shown as mean7standard deviation. BM: bone
marrow; PB: peripheral blood. *Po0.05 in comparison to normal/decreased or normal/increased cases.
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In order to investigate the predictive value of the patterns
of expression of tetraspanin and other related molecules
during normal B-cell maturation, a supervised prediction model
was built to identify three classes: (1) BM BCP; (2) mature
BM, PB and lymph node B lymphocytes; and (3) BM PC.
For this purpose a training set which included all normal
B-cell populations (n¼ 20) and a leave-one-out crossvalida-
tion scheme were used. The predictor contained eight
phenotypic variables and assigned the withheld sample to the
appropriate class with 100% accuracy. Once this model
was tested with the neoplastic samples (n¼ 51) it showed
an overall accuracy of 88%, the percentage of correctly
classified samples ranging from 70% of the PC dyscrasias
to 100% of all mature B-cell leukemias and lymphomas. Despite
this, it should be noted that combined use of the five tetraspanin
and three tetraspanin-associated molecules studied here al-
lowed the specific (100% specificity) distinction between
normal and neoplastic B cells with a sensitivity ranging from
20% in PC dyscrasias and 69% in B-cell chronic lymphopro-
liferative disorders other than B-CLL to 100% in both BCP-ALL
and B-CLL.
Discussion
Analysis of the reactivity for the CD9, CD37, CD53 and
CD81 tetraspanin antigens showed the occurrence of important
changes in their expression during normal B-cell maturation.
Accordingly, our results show the existence of three different
combinations of tetraspanin expression during B-cell matura-
tion: CD9/CD81 in the early BM BCP, CD37/CD53 in mature/
peripheral B lymphocytes, and CD9/CD53 in PC that have
passed through secondary lymphoid tissues and reentered the
BM.
Among other processes, tetraspanins are involved in cell
adhesion.57,58 Thus, the observation of distinct patterns of
tetraspanin expression during B-cell maturation may reflect the
occurrence of different cellular interactions and homing proper-
ties. In line with this hypothesis, the more mature BM B
lymphocytes lost CD9 and CD81 when they got ready to migrate
and leave the BM. These findings are in line with previous
observations in carcinomas, where loss of any of these proteins
has been shown to correlate with a worse prognosis,8 associated
with a higher metastatic potential. The molecular basis of the
differential pattern of tetraspanin expression remains unknown,
since of the four antigens mentioned, only the promoters of the
CD959 and CD53 genes60 have been partially characterized.
Alternative gene expression of CD9, CD37 or CD53 has also
been detected in different types of renal61 and prostate
carcinomas.62
The expression of at least three different combinations
of tetraspanin antigens during normal B-cell maturation
suggests that distinct patterns of expression of these proteins
might also be found in B-cell neoplasias. Overall, the analysis
of the pattern of expression of the four tetraspanin antigens
indicated that there is a relatively high degree of correlation
between normal and neoplastic cells, and that the tumors
can be classified according to their putative stage of maturation
arrest based on the pattern of tetraspanin expression. Accord-
ingly, mature/peripheral B-cell leukemias and lymphomas
tended to express high levels of CD37 and CD53, while
those derived from BCP-ALL and clonal PC coexpressed
CD9 with either CD81 or CD53, respectively. Based on these
markers, only two MM cases showing the highest amounts of
CD81 on PC were misclassified. Despite these phenotypic
similarities, neoplastic B-cells showed variable levels of
expression of one or more of these proteins that were frequently
expressed at abnormally low or high amounts per cell.
Interestingly, some of these phenotypic aberrations
were common to most patients within a specific disease group.
In fact, CD81 was aberrantly underexpressed in virtually
all B-CLL cases and in up to 75% of BCP-ALL patients; in turn,
CD63 was overexpressed in around three quarters of all BCP-
ALL and B-CLL patients. An intriguing finding regarding CD63
expression is its upregulation on MGUS, but not on myeloma-
tous PC, in comparison to normal PC. CD63 is mostly an
intracellular antigen present on the membrane of endosomes
and other intracellular vesicles that becomes expressed
on the cell surface after degranulation.63,64 Interestingly,
we have recently shown that clonal PC from MGUS but
not MM show an increased surface expression of HLA-I
molecules;65 further investigations are required to clarify
the potential relationship between the increased HLA-I and
CD63 expression on clonal PC from MGUS. Altogether,
these results point out the utility of these tetraspanin molecules
in combination with other B-cell-associated markers, not
only for the diagnostic classification of B-cell neoplasias but
also for the identification of aberrant phenotypes that could be
used for monitoring minimal disease levels.54,66,67 Although the
exact significance of such phenotypic aberrations still needs to
be established, they might reflect specific genetic abnormalities.
In fact a careful comparison of B-CLL/PLL cases with 13q- (n¼ 6)
and those who did not have these abnormalities (n¼ 14) showed
that the intensity of expression of CD21 was significantly higher
in the former group of patients (MFI of CD21: 58740 vs 26726;
P¼ 0.05). However, due to the relatively limited number
of cases included in each specific cytogenetic category in
most diagnostic groups, definitive conclusions about these
phenotypic/genotypic associations require further study in
larger groups of patients. Nevertheless, it should be noted that
once a well-characterized diagnostic entity such as B-CLL
was considered the pattern of expression of CD9 and CD53,
tetraspanins were associated with the pattern of in vivo
tissue involvement. Accordingly, abnormally high reactivity for
CD53 was associated with greater PB and lymph
node infiltration. Previous studies have shown that ligation of
CD53 antigen protects lymphoid cells from apoptosis,17
an important property for mature/peripheral memory lympho-
cytes. Accordingly, overexpression of CD53 could render
B-CLL cells more adapted to survive in PB and lymph nodes.
In contrast, decreased CD9 expression on B-CLL cells
was related to a higher BM involvement and decreased numbers
of platelets in PB. CD9 has been shown to function as a motility/
migration brake when reintroduced in some carcinoma cells.9
At the same time it has been associated with a higher metastatic
potential,8 which could help to explain the relationship
observed between CD9 expression and the pattern of BM
involvement.
In summary, in the present study, we show that during
normal B-cell maturation there are two switches in tetraspanin
antigen expression occurring in the BM, in the transition
from CD10þ BCP to CD10- B lymphocytes, and later on
during terminal differentiation into antibody-secreting BM PC.
Interestingly, the pattern of tetraspanin antigen expression
on the surface of neoplastic B cells shows great similarities
to their normal counterpart allowing discrimination between
different B-cell neoplasms. Despite this, neoplastic B cells
frequently show aberrant expression of specific tetraspanin
molecules that could be used for the investigation of minimal
disease.
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